Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 30;1(1):CD001989.
doi: 10.1002/14651858.CD001989.pub3.

Interventions for acute non-arteritic central retinal artery occlusion

John C Lin  1 , Sophia Song  1 , Sueko M Ng  2 , Ingrid U Scott  3 , Paul B Greenberg  4
Affiliations

Interventions for acute non-arteritic central retinal artery occlusion

John C Lin et al. Cochrane Database Syst Rev. .

Abstract

Background: Acute non-arteritic central retinal artery occlusion (CRAO) occurs as a sudden interruption of the blood supply to the retina and typically results in severe loss of vision in the affected eye. Although many therapeutic interventions have been proposed, there is no generally agreed upon treatment regimen.

Objectives: To assess the effects of treatments for acute non-arteritic CRAO.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2022, Issue 2); Ovid MEDLINE; Embase.com; PubMed; Latin American and Caribbean Health Sciences Literature Database (LILACS); ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 15 February 2022.

Selection criteria: We included randomized controlled trials (RCTs) comparing any interventions with another treatment in participants with acute non-arteritic CRAO in one or both eyes. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodology and graded the certainty of the body of evidence for primary (mean change in best-corrected visual acuity [BCVA]) and secondary (quality of life and adverse events) outcomes using the GRADE classification.

Main results: We included six RCTs with 223 total participants with acute non-arteritic CRAO; the studies ranged in size from 10 to 84 participants. The included studies varied geographically: one in Australia, one in Austria and Germany, two in China, one in Germany, and one in Italy. We were unable to conduct any meta-analyses due to study heterogeneity. None of the included studies compared the same pair of interventions: 1) tissue plasminogen activator (t-PA) versus intravenous saline; 2) t-PA versus isovolemic hemodilution, eyeball massage, intraocular pressure reduction, and anticoagulation; 3) nitroglycerin, methazolamide, mecobalamin tablets, vitamin B1 and B12 injections, puerarin and compound anisodine (also known as 654-2) along with oxygen inhalation, eyeball massage, tube expansion, and anticoagulation compared with and without intravenous recombinant tissue plasminogen activator (rt-PA); 4) transcorneal electrical stimulation (TES) with 0 mA versus with 66% of the participant's individual electrical phosphene threshold (EPT) at 20 Hz (66%) versus with 150% of the participant's individual EPT (150%) at 20 Hz; 5) ophthalmic artery branch retrograde thrombolysis versus superselective ophthalmic artery thrombolysis; and 6) pentoxifylline versus placebo. There was no evidence of an important difference in visual acuity between participants treated with t-PA versus intravenous saline (mean difference [MD] at 1 month -0.15 logMAR, 95% confidence interval [CI] -0.48 to 0.18; 1 study, 16 participants; low certainty evidence); t-PA versus isovolemic hemodilution, eyeball massage, intraocular pressure reduction, and anticoagulation (MD at 1 month -0.00 logMAR, 95% CI -0.24 to 0.23; 1 study, 82 participants; low certainty evidence); and TES with 0 mA versus TES with 66% of EPT at 20 Hz versus TES with 150% of EPT at 20 Hz. Participants treated with t-PA experienced higher rates of serious adverse effects. The other three comparisons did not report statistically significant differences. Other studies reported no data on secondary outcomes (quality of life or adverse events). AUTHORS' CONCLUSIONS: The current research suggests that proposed interventions for acute non-arteritic CRAO may not be better than observation or treatments of any kind such as eyeball massage, oxygen inhalation, tube expansion, and anticoagulation, but the evidence is uncertain. Large, well-designed RCTs are necessary to determine the most effective treatment for acute non-arteritic CRAO.

PubMed Disclaimer

Conflict of interest statement

John C Lin: none known Sophia Song: none known Sueko M Ng: none known Ingrid U Scott: none known Paul B Greenberg: none known

Figures

1
1
Study flow diagram
2
2
1.1
1.1. Analysis
Comparison 1: Tissue plasminogen activator (t‐PA) versus standard treatment, Outcome 1: Mean change in best‐corrected visual acuity from baseline (logMAR)
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Chen 2011 {published data only}
    1. ACTRN12608000441314. Study of the efficacy of intravenous tissue plasminogen activator (tPA) in the treatment of acute central retinal artery occlusion (CRAO). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12608000441314 (first received 23 August 2008).
    1. Chen CS, Lee AW, Campbell B, Lee T, Paine M, Fraser C, et al. Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a randomized, controlled trial. Stroke 2011;42(8):2229‐34. - PubMed
    1. Chen CS, Lee AW, Campbell B, Paine M, Lee T, Fraser C, et al. Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion. International Journal of Stroke 2011;6(1):87-9. - PubMed
    1. Lee A, Chen C, Campbell B, Griggs J. A randomized controlled trial of intravenous tissue plasminogen activator in central retinal artery occlusion. International Journal of Stroke 2011;6 Suppl 1:23. - PubMed
    1. Lee A, Chen C, Lee T, Campbell. Intra-venous tissue plasminogen activator for acute central retinal artery occlusion: a first randomized controlled trial. Stroke 2011;42:e261. - PubMed
EAGLE {published data only}
    1. Callizo J, Feltgen N, Pantenburg S, Wolf A, Neubauer AS, Jurklies B, et al. Cardiovascular risk factors in central retinal artery occlusion: results of a prospective and standardized medical examination. Ophthalmology 2015;122(9):1881‐8. - PubMed
    1. DRKS00000088. Multicenter trial of the European Assessment Group for Lysis in the Eye (EAGLE): therapy of the central retinal artery occlusion: lysis versus conservative treatment. www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DR... (first received 19 February 2009).
    1. Junker B, Pantenburg S, Callizo J, Schmoor C, Schumacher M, Feltgen N, et al. Predictors of prognosis and treatment outcome in central retinal artery occlusion: results of the randomized multicenter EAGLE trial. Investigative Ophthalmology & Visual Science 2014;55(13):684.
    1. London NJS, Brown GC. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Evidence-Based Ophthalmology 2011;12(2):96‐7. - PubMed
    1. NCT00637468. EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye. clinicaltrials.gov/show/NCT00637468 (first received 18 March 2008).
Incandela 2002 {published data only}
    1. Incandela L, Cesarone MR, Belcaro G, Steigerwalt R, De Sanctis MT, Nicolaides AN, et al. Treatment of vascular retinal disease with pentoxifylline: a controlled, randomized trial. Angiology 2002;53(Suppl 1):S31-4. - PubMed
Naycheva 2013 {published data only}
    1. Naycheva L, Schatz A, Willmann G, Bartz-Schmidt KU, Zrenner E, Rock T, et al. Transcorneal electrical stimulation in patients with retinal artery occlusion: a prospective, randomized, sham-controlled pilot study. Ophthalmology and Therapy 2013;2(1):25‐39. - PMC - PubMed
Wang 2017 {published data only}
    1. Wang R, Qian L, Wang Y, Zheng Y, Du S, Lei T, et al. Evaluation of ophthalmic artery branch retrograde intervention in the treatment of central retinal artery occlusion (CRAO). Medical Science Monitor 2017;23:114‐20. - PMC - PubMed
Wu 2016 {published data only}
    1. Wu X J, Gao F, Liu X, Zhao Q. Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion. Experimental and Therapeutic Medicine 2016;12(4):2617‐21. - PMC - PubMed

References to studies excluded from this review

ACTRN12609001042235 {published data only}
    1. ACTRN12609001042235. Clinical study of vitreous surgery with direct central retinal artery massage for the treatment of central retinal artery occlusion. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320877 (first received 7 December 2009).
Arnold 2005 {published data only}
    1. Arnold M, Koerner U, Remonda L, Nedeltchev K, Mattle HP, Schroth G, et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. Journal of Neurology, Neurosurgery & Psychiatry 2005;76(2):196-9. - PMC - PubMed
Atebara 1995 {published data only}
    1. Atebara NH, Brown GC, Cater J. Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Ophthalmology 1995;102(12):2029-34. - PubMed
Augsburger 1980 {published data only}
    1. Augsburger JJ, Magargal LE. Visual prognosis following treatment of acute central retinal artery obstruction. British Journal of Ophthalmology 1980;64(12):913-7. - PMC - PubMed
Bedersdorfer 2022 {published data only}
    1. Bedersdorfer M, Rickmann A, Bisorca-Gassendorf L, Szurman P, Boden KT, Seitz B, et al. Intravenous fibrinolysis for nonarteritic central retinal artery occlusion—a treatment option? Ophthalmologe 2022;119(Suppl 1):98-101. - PubMed
Callizo 2009 {published data only}
    1. Callizo CH, Kroll JP, Mennel S, Schmidt J, Meyer C. Radial optic neurotomy for central retinal vein occlusion: long-term retinal perfusion outcome. Ophthalmologica 2009;223(5):313-9. - PubMed
ChiCTR2000038317 {published data only}
    1. ChiCTR2000038317. Treatment regimen multicenter clinical study of retinal artery occlusion after 12 hours. www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000038317 (first received 17 September 2020).
Drago 1982 {published data only}
    1. Drago F, Amico-Roxas M, Matera M. Effects of L-acetyl-carnitine on the electroretinographic responses in patients with central retinal artery occlusion. Acta Therapeutica 1982;8(3):201-8.
Fernández 2000 {published data only}
    1. Fernández FJ, Guelbenzu S, Barrena C, Larrosa JM. Selective ophthalmic artery fibrinolysis in acute central retinal artery occlusion. Archivos de la Sociedad Española de Oftalmología 2000;2:1‐7. - PubMed
Gu 1999 {published data only}
    1. Gu WZ, Pu RX, Wang YG, Zhou LX, Dong L, Liu H. Analysis on the curative effects of GEQI oral in treatment of retinal artery occlusion. Aerospace Medicine 1999;10(2):64-6.
Hayreh 2008 {published data only}
    1. Hayreh SS. Intra-arterial thrombolysis for central retinal artery occlusion. British Journal of Ophthalmology 2008;92(5):585-7. - PubMed
Holschermann 2005 {published data only}
    1. Holschermann H, Krombach C, Jung A, Jacobi F, Tillmanns H, Weinand F. Treatment of acute central retinal artery occlusion with the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban. Thrombosis & Haemostasis 2005;94(3):684-6. - PubMed
Iwafune 1980 {published data only}
    1. Iwafune Y, Yoshimoto H. Clinical use of pentoxifylline in haemorrhagic disorders of the retina. Pharmatherapeutica 1980;2(7):429-38. - PubMed
JPRN‐jRCT2031210280 {published data only}
    1. JPRN-jRCT2031210280. QT/QTc evaluation study in healthy Japanese adult male subjects. https://jrct.niph.go.jp/en-latest-detail/jRCT2031210280 (first received 27 August 2021).
JPRN‐jRCT2032190199 {published data only}
    1. JPRN-jRCT2032190199. Safety and effectiveness of transdermal electrical stimulation for central retinal artery occlusion. https://jrct.niph.go.jp/pages/en-detail/14238/jRCT/3 (first received 3 February 2020).
JPRN‐jRCTs031180441 {published data only}
    1. JPRN-jRCTs031180441. Intra-retinal arterial fibrinolysis. https://jrct.niph.go.jp/en-latest-detail/jRCTs031180441 (first received 28 March 2019).
JPRN‐jRCTs041190079 {published data only}
    1. JPRN-jRCTs041190079. t-PA trial for central retinal artery occlusion. https://jrct.niph.go.jp/en-latest-detail/jRCTs041190079 (first received 19 November 2019).
JPRN‐UMIN000012161 {published data only}
    1. JPRN-UMIN000012161. Local intraarterial fibrinolysis in central retinal artery occlusion. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000012161 (first received 30 October 2013).
JPRN‐UMIN000022972 {published data only}
    1. JPRN-UMIN000022972. Study of the efficacy and safety of intra-retinal arterial fibrinolysis for central retinal artery occlusion. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000022972 (first received 1 July 2016).
JPRN‐UMIN000023979 {published data only}
    1. JPRN-UMIN000023979. Phase 1/2 clinical trial to evaluate the safety and efficacy of daily intravitreal injections of KUS121 for three days in patients with non-arteritic central retinal artery occlusion. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000023979 (first received 15 September 2016).
JPRN‐UMIN000036219 {published data only}
    1. JPRN-UMIN000036219. Safety and effectiveness of transdermal electrical stimulation for central retinal artery occlusion. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040991 (first received 1 April 2019).
Kattah 2002 {published data only}
    1. Kattah JC, Wang DZ, Reddy C. Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion. Archives of Ophthalmology 2002;120(9):1234-6. - PubMed
Makhkamova 2015 {published data only}
    1. Makhkamova D, Kasimova M. Prostaglandin F2α analogues in the treatment of the chronic ocular ischaemic syndrome. Neuro-Ophthalmology 2015;39:S50.
Mehboob 2021 {published data only}
    1. Mehboob MA, Khan A, Mukhtar A. Efficacy of YAG laser embolysis in retinal artery occlusion. Pakistan Journal of Medical Sciences 2021;37(1):1‐5. - PMC - PubMed
Mendes 2018 {published data only}
    1. Mendes JF, Amorim J, Calvao-Santos G. Systemic intravenous abciximab: a novel treatment for acute central retinal artery occlusion? Acta Ophthalmologica 2018;96(1):e101-2. - PubMed
Neubauer 2000 {published data only}
    1. Neubauer AS, Mueller AJ, Schriever S, Gruterich M, Ulbig M, Kampik A. Minimally invasive therapy for clinically complete central retinal artery occlusion—results and meta-analysis of literature [Minimal invasive Therapie bei klinisch komplettem Zentralarterienverschluss—eigene Ergebnisse und Literaturvergleich]. Klinische Monatsblatter fur Augenheilkunde 2000;217(1):30-6. - PubMed
Noble 2009 {published data only}
    1. Noble PJ, Kertes J. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. Evidence-Based Ophthalmology 2009;10(2):102-3. - PubMed
Pettersen 2005 {published data only}
    1. Pettersen JA, Hill MD, Demchuk AM, Morrish W, Hudon ME, Hu W, et al. Intra-arterial thrombolysis for retinal artery occlusion: the Calgary experience. Canadian Journal of Neurological Sciences 2005;32(4):507-11. - PubMed
Richard 1999 {published data only}
    1. Richard G, Lerche RC, Knospe V, Zeumer H. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology 1999;106(4):768-73. - PubMed
Rumelt 1999 {published data only}
    1. Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. American Journal of Ophthalmology 1999;128(6):733-8. - PubMed
Schmidt 1992 {published data only}
    1. Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. American Journal of Ophthalmology 1992;113(4):429-34. - PubMed
Schumacher 1993 {published data only}
    1. Schumacher M, Schmidt D, Wakhloo AK. Intra-arterial fibrinolytic therapy in central retinal artery occlusion. Neuroradiology 1993;35(8):600-5. - PubMed
Tan 2009 {published data only}
    1. Tan CQB, Liao S, Wu L. Curative effect of combination of traditional Chinese medicine and Western medicine for the treatment of retinal artery occlusion. International Journal of Ophthalmology 2009;9(10):1913-5.
TCTR20210510007 {published data only}
    1. TCTR20210510007. Optical coherence tomography angiography findings in patients with acute non-arteritic central retinal artery occlusion treated with carbogen inhalation. www.thaiclinicaltrials.org/show/TCTR20210510007 (first received 10 May 2021).
Telek 2019 {published data only}
    1. Telek HH. Effects of selenium and melatonin on ocular ischemic syndrome. BioMed Research International 2019 Dec 6 [Epub ahead of print]. [DOI: 10.1155/2019/8080564] - DOI - PMC - PubMed
Weber 1998 {published data only}
    1. Weber J, Remonda L, Mattle HP, Koerner U, Baumgartner RW, Sturzenegger M, et al. Selective intra-arterial fibrinolysis of acute central retinal artery occlusion. Stroke 1998;29(10):2076-9. - PubMed
Werner 2004 {published data only}
    1. Werner D, Michalk F, Harazny J, Hugo C, Daniel WG, Michelson G. Accelerated reperfusion of poorly perfused retinal areas in central retinal artery occlusion and branch retinal artery occlusion after a short treatment with enhanced external counterpulsation. Retina 2004;24(4):541-7. - PubMed

References to ongoing studies

JPRN‐jRCT2021190013 {published data only}
    1. JPRN-jRCT2021190013. Phase IIa study (doctor-led trial) for the efficacy and safety of SJP-0008 in central retinal artery occlusion. https://jrct.niph.go.jp/en-latest-detail/jRCT2021190013 (first received 11 December 2019).
JPRN‐jRCTs031180280 {published data only}
    1. JPRN-jRCTs031180280. The efficacy of hydrogen eye drop for retinal artery occlusion. https://jrct.niph.go.jp/en-latest-detail/jRCTs031180280 (first received 14 March 2019).
    1. JPRN-UMIN000015528. The efficacy of hydrogen eye drop for the ischemia-reperfusion injury of retinal artery occlusion. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018028 (first received 27 October 2014).
NCT03197194 {published data only}
    1. NCT03197194. A phase III randomized, blind, double dummy, multicenter study assessing the efficacy and safety of IV thrombolysis (Alteplase) in patients with acute central retInal artery occlusion. clinicaltrials.gov/show/NCT03197194 (first received 23 June 2017).
NCT04526951 {published data only}
    1. Aamodt AH, Jorstad O, Kraglund KL, Sandset EC, Vanacker P, Murphy S, et al. TENecteplase in Central Retinal Artery Occlusion (TEN-CRAOS): a prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25mg/kg+placebo vs. ASA+placebo (2 arms with 1: 1 block randomization). European Journal of Neurology 2020;27 Suppl 1:80.
    1. EUCTR2018-002546-36-FI. Tenecteplase in central retinal artery occlusion study (TenCRAOS): a randomized controlled trial of acute clotsolving medication in central retinal artery occlusion. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-002546-36-FI (first received 4 December 2020).
    1. NCT04526951. The TENecteplase in Central Retinal Artery Occlusion Study (TenCRAOS). clinicaltrials.gov/show/NCT04526951 (first received 26 August 2020).
    1. Ryan S, Aaomdt A. Tenecteplase in central retinal artery occlusion study (tencraos). International Journal of Stroke 2021;16(2 Suppl):74.
REVISION {published data only}
    1. Engelmann K, on behalf of the RESOLVE study group. Safety and efficacy of ranibizumab treatment in patients with diabetic macular oedema: 12-months results of the RESOLVE study. Diabetologia 2009;52:S31.
    1. NCT04965038. Early reperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion. clinicaltrials.gov/ct2/show/NCT04965038 (first received 16 July 2021).
    1. Schultheiss M, Spitzer MS, Hattenbach LO, Poli S. Update on intravenous lysis treatment: the REVISION trial [Update intravenöse Lysetherapie: Die REVISION-Studie]. Der Ophthalmologe 2021;118(11):1107–12. - PubMed

Additional references

AAO 2019
    1. American Academy of Ophthalmology. Retinal and ophthalmic artery occlusions Preferred Practice Pattern® 2019. www.aao.org/preferred-practice-pattern/retinal-ophthalmic-artery-occlusi... (accessed 22 November 2022).
Adenuga 2015
    1. Adenuga OO, Ramyll AV, Odugbo OP, Oyediji FJ. Prevalence, pattern and risk factors for retinal vascular occlusions in a tertiary hospital in Jos, Nigeria. Nigerian Journal of Medicine 2015;24(4):331-6. - PubMed
Arora 1999
    1. Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. Journal of the American College of Cardiology 1999;33(7):1833-40. - PubMed
Barnes 1980
    1. Barnes RW. Hemodynamics for the vascular surgeon. JAMA Surgery 1980;115(2):216-23. - PubMed
Bath 2004
    1. Bath PMW, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No: CD000162. [DOI: 10.1002/14651858.CD000162.pub2] - DOI - PubMed
Busse 1982
    1. Busse R, Bassenge E. Effect of nitrates, nitrate-like substances, calcium antagonists and beta-adrenergic receptor blockers on peripheral circulation [Einfluss von Nitraten, nitratähnlichen Substanzen, Calcium-Antagonisten und beta-Rezeptorenblockern auf den peripheren Kreislauf]. Herz 1982;7(6):388-405. - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 8 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.
Deeks 2019
    1. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley & Sons, 2019:241-84.
Deutsch 1983
    1. Deutsch TA, Read JS, Ernest JT, Goldstick TK. Effects of oxygen and carbon dioxide on the retinal vasculature in humans. Archives of Ophthalmology 1983;101(8):1278-80. - PubMed
Dumitrascu 2020
    1. Dumitrascu O, Newman N, Biousse V. Thrombolysis for central retinal artery occlusion in 2020: time is vision! Journal of Neuro-Ophthalmology 2020;40(3):333-45. - PMC - PubMed
Feltgen 2006
    1. Feltgen N, Neubauer A, Jurklies B, Schmoor C, Schmidt D, Wanke J, et al. Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244(8):950-6. - PubMed
Ffytche 1974a
    1. Ffytche TJ, Bulpitt CJ, Kohner EM, Archer D, Dollery CT. Effect of changes in intraocular pressure on the retinal microcirculation. British Journal of Ophthalmology 1974;58(5):514-22. - PMC - PubMed
Ffytche 1974b
    1. Ffytche TJ. A rationalization of treatment of central retinal artery occlusion. Transactions of the Ophthalmological Societies of the United Kingdom 1974;94(2):468-79. - PubMed
Flaxel 2020
    1. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Retinal and Ophthalmic Artery Occlusions Preferred Practice Pattern®. Ophthalmology 2020;127(2):259-87. - PubMed
Frampton 1995
    1. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs & Aging 1995;7(6):480-503. - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6. - PMC - PubMed
Harvey 2000
    1. Harvey PA, Winder S, Talbot JF. Trabeculectomy for central retinal artery occlusion. Eye 2000;14(Pt 2):256-7. - PubMed
Hausmann 1991
    1. Hausmann N, Richard G. Effect of high dose steroid bolus on occlusion of ocular central artery: angiographic study. BMJ 1991;303(6815):1445-6. - PMC - PubMed
Hayreh 1980
    1. Hayreh SS, Kolder HE, Weingeist TA. Central retinal artery occlusion and retinal tolerance time. Ophthalmology 1980;87(1):75-8. - PubMed
Hayreh 2018
    1. Hayreh SS. Central retinal artery occlusion. Indian Journal of Ophthalmology 2018;66(12):1684-94. - PMC - PubMed
Higgins 2019
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley & Sons, 2019.
Huang 2022
    1. Huang L, Wang Y, Zhang R. Intravenous thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis. Journal of Neurology 2022;264(4):1825-33. - PubMed
Iwafune 1980
    1. Iwafune Y, Yoshimoto H. Clinical use of pentoxifylline in haemorrhagic disorders of the retina. Pharmatherapeutica 1980;2(7):429-38. - PubMed
Kido 2020
    1. Kido A, Tamura H, Ikeda HO, Miyake M, Hiragi S, Tsujikawa A. Nationwide incidence of central retinal artery occlusion in Japan: an exploratory descriptive study using the National Database of Health Insurance Claims (2011-2015). BMJ Open 2020;10(9):e041104. [DOI: 10.1136/bmjopen-2020-041104.] - DOI - PMC - PubMed
Kieswetter 1983
    1. Kieswetter H, Korber N, Jung F, Reim M. Rheologic findings in patients with acute central retinal artery occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 1983;220(2):92-5. - PubMed
Lavin 2018
    1. Lavin P, Patrylo M, Hollar M, Espaillat KB, Kirshner H, Schrag M. Stroke risk and risk factors in patients with central retinal artery occlusion. American Journal of Ophthalmology 2018;196:96-100. - PubMed
Leavitt 2011
    1. Leavitt JA, Larson TA, Hodge DO, Gullerud RE. The incidence of central retinal artery occlusion in Olmsted County, Minnesota. American Journal of Ophthalmology 2011;152(5):820-3.e2. [DOI: 10.1016/j.ajo.2011.05.005] - DOI - PMC - PubMed
Mac Grory 2020
    1. Mac Grory B, Nackenoff A, Poli S, Spitzer MS, Nedelmann M, Guillon BP, et al. Intravenous fibrinolysis for central retinal artery occlusion. Stroke 2020;51(7):2018-25. - PubMed
Mac Grory 2021
    1. Mac Grory B, Schrag M, Biousse V, Furie KL, Gerhard-Herman M, Lavin PJ, et al. Management of central retinal artery occlusion: a scientific statement from the American Heart Association. Stroke 2021;52(6):e282-94. - PubMed
Mason 2007
    1. Mason JO 3rd, Nixon PA, Albert MA Jr. Trans-luminal nd:YAG laser embolysis for branch retinal artery occlusion. Retina 2007;27(5):573-7. - PubMed
Neubauer 2000
    1. Neubauer AS, Mueller AJ, Schriever S, Grüterich M, Ulbig M, Kampik A. Minimally invasive therapy for clinically complete central retinal artery occlusion—results and meta-analysis of literature [Minimal invasive Therapie bei klinisch komplettem Zentralarterienverschluss—eigene Ergebnisse und Literaturvergleich]. Klin Monbl Augenheilkd 2000;217(1):30-6. - PubMed
Noble 2008
    1. Noble J, Weizblit N, Baerlocher MO, Eng KT. Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review. British Journal of Ophthalmology 2008;92(5):588-93. - PubMed
Opremcak 2008
    1. Opremcak E, Rehmar AJ, Ridenour CD, Borkowski LM, Kelley JK. Restoration of retinal blood flow via translumenal Nd:YAG emblysis/embolectomy (TYL/E) for central and branch retinal artery occlusion. Retina 2008;28(2):226-35. - PubMed
Page 2018
    1. Page PS, Khattar NK, White AC, Cambon AC, Brock GN, Rai SN, et al. Intra-arterial thrombolysis for acute central retinal artery occlusion: a systematic review and meta-analysis. Frontiers in Neurology 2018;9(76). [DOI: 10.3389/fneur.2018.00076] - DOI - PMC - PubMed
Page 2020
    1. Page MJ, Higgins JPT, Sterne JAC. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.
Pettersson 2006
    1. Pettersson T, Bondesson S, Cojocaru D, Ohlsson O, Wackenfors A, Edvinsson L. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovascular Disorders 2006;6:28. - PMC - PubMed
Rassam 1993
    1. Rassam SM, Patel V, Kohner EM. The effect of acetazolamide on the retinal circulation. Eye 1993;7(Pt 5):697-702. - PubMed
Ratra 2012
    1. Ratra D, Dhupper M. Retinal arterial occlusions in the young: systemic associations in Indian population. Indian Journal of Ophthalmology 2012;60(2):95-100. - PMC - PubMed
RevMan Web 2022 [Computer program]
    1. Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.
Rosignoli 2022
    1. Rosignoli L, Chu ER, Carter JE, Johnson DA, Sohn JH, Bahadorani S. The effects of hyperbaric oxygen therapy in patients with central retinal artery occlusion: a retrospective study, systematic review, and meta-analysis. Korean Journal of Ophthalmology 2022;36(2):108-13. - PMC - PubMed
Rumelt 1999
    1. Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. American Journal of Ophthalmology 1999;128(6):733-8. - PubMed
Saxena 2013
    1. Saxena S, Mishra N, Meyer CH, Akduman L. Ischaemia-reperfusion injury in central retinal artery occlusion. Case Reports 2013;2013:bcr2013201415. - PMC - PubMed
Schmetterer 1996
    1. Schmetterer L, Lexer F, Findl O, Graselli U, Eichler HG, Wolzt M. The effect of inhalation of different mixtures of O2 and CO2 on ocular fundus pulsations. Experimental Eye Research 1996;63(4):351-5. - PubMed
Schmidt 1992
    1. Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. American Jounral of Ophthalmology 1992;113(4):429-34. - PubMed
Schrag 2015
    1. Schrag M, Youn T, Schindler J, Kirshner H, Greer D. Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis. JAMA Neurology 2015;72(10):1148-54. - PubMed
Seiffge 1981
    1. Seiffge D, Kiesewetter H. Effect of pentoxifylline on single red cell deformability. Klin Wochenschr 1981;16(59):1271-2. - PubMed
Sharma 2013
    1. Sharma U, Ramsey HK, Tak T. The role of enhanced external counter pulsation therapy in clinical practice. Clinical Medicine & Research 2013;11(4):226-32. - PMC - PubMed
Shilpa 2015
    1. Shilpa YD, Kaplana BN, Sadiqulla M. Optical coherence tomogram and demographic profile in central retinal artery occlusion: a South Indian study. Egyptian Retina Journal 2015;3(1):10-4.
Shilpa 2018
    1. Shila YD, Kalpana BN, Devaru S. Bilateral central retinal artery occlusion in a case of eclampsia. Egyptian Retina Journal 2018;5(2):50-2.
Sho 2005
    1. Sho K, Takahashi K, Fukuchi T, Matsumura M. Quantitative evaluation of ischemia-reperfusion injury by optical coherence tomography in the rat retina. Japanese Journal of Ophthalmology 2005;49(2):109-13. - PubMed
Tobalem 2018
    1. Tobalem S, Schutz JS, Chronopoulos A. Central retinal artery occlusion—rethinking retinal survival time. BMC Ophthalmology 2018;18(1):101. - PMC - PubMed
Wang 2021
    1. Wang X, Liu Y, Suo Y, Qin D, Ren M, Lei R, et al. Intravenous recombinant tissue-type plasminogen activator thrombolysis for acute central retinal artery occlusion. Journal of Craniofacial Surgery 2021;32(1):313-6. - PubMed
Weber 2018
    1. Weber AC, Blandford AD, Costin BR, Perry JD. Effect of mannitol on globe and orbital volumes in humans. European Journal of Ophthalmology 2018;28(2):163-7. - PubMed
Wiman 1978
    1. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978;272:549-50. - PubMed
Wolf 1989
    1. Wolf S, Hoberg A, Bertram B, Jung F, Kiesewetter H, Reim M. Video fluorescein angiography follow-up of patients with retinal artery occlusion. Klinische Monatsblatter fur Augenheilkunde 1989;195(3):154-60. - PubMed
Youn 2018
    1. Youn TS, Lavin P, Patrylo M, Schindler J, Kirshner H, Greer DM, et al. Current treatment of central retinal artery occlusion: a national survey. Journal of Neurology 2018;265(2):330-5. - PubMed
Zairi 2015
    1. Zairi I, Mzoughi K, Jnifene Z, Moussa FB, Kammoun S, Fennira S, et al. Ischemic cardiomyopathy revealed by central retinal artery occlusion (CRAO). Pan African Medical Journal 2015 Nov 17 [Epub ahead of print]. [DOI: 10.11604/pamj.2015.22.250.7308] - DOI - PMC - PubMed

References to other published versions of this review

Fraser 2002
    1. Fraser S, Siriwardena D. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No: CD001989. [DOI: 10.1002/14651858.CD001989] - DOI - PubMed
Fraser 2009
    1. Fraser SG, Adams W. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No: CD001989. [DOI: 10.1002/14651858.CD001989.pub2] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources